Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
-
Published:2019-04-03
Issue:1
Volume:7
Page:
-
ISSN:2051-1426
-
Container-title:Journal for ImmunoTherapy of Cancer
-
language:en
-
Short-container-title:j. immunotherapy cancer
Author:
Pai Sara I.ORCID, Faivre Sandrine, Licitra Lisa, Machiels Jean-Pascal, Vermorken Jan B., Bruzzi Paolo, Gruenwald Viktor, Giglio Raul E., Leemans C. René, Seiwert Tanguy Y., Soulieres Denis
Subject
Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy
Reference6 articles.
1. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Wodern F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for recurrent squamous cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67. 2. Cohen EEW, Harrington KJ, Tourneau CL, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Wang Y, Tuozzo A, Cheng JD, Swaby R, Soulieres D. Pembrolizumab vs standard of care for recurrent or metastatic head and neck squamous cell carcinoma: Phase 3 Keynote −040 Trial. In: ESMO Meeting, LBA45; 2017. 3. Soulieres D, Cohen EEW, Tourneau CL, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng JD, Swaby R, Harrington KJ. Updated survival results of KEYNOTE-040 study of pembrolizumab vs standard of care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma. Chicago: AACR Meeting; 2018. p. 2018. 4. Cohen EEW, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ, KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (JEYNOTE-040): a randomised open-Labe, phase 3 study. Lancet. 2019;393(10167):156–67. 5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|